From a mechanistic point of view, ICIs are monoclonal antibodies that antagonize the pathways for programmed cell death receptor 1 (PD‐1), programmed cell death ligand 1 (PD‐L1), cytotoxic T‐lymphocyte–associated protein 4 (CTLA‐4) and could activate the immune system against cancer cells (2–4). This evidence concerns the gene CD274 and cancer.